SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib.
Li S, Zhao S, Liang N, Zhang S, Zhang L, Zhou L, Liu A, Cao X, Tian J, Yu Y, et al. Gastric Cancer. 2023 Sep; 26(5):677-690. Epub 2023 May 24.